Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses

Vaccine

Volumn 26, Issue 17, 2008, Pages 2164-2174

  Liniger, Matthias ^a   Zuniga, Armando ^a   Tamin, Azaibi ^b   Azzouz Morin, Teldja N ^a   Knuchel, Marlyse ^a   Marty, Rene R ^a   Wiegand, Marian ^a   Weibel, Sara ^a   Kelvin, David ^c   Rota, Paul A ^b   Naim, Hussein Y ^a  

^a Berna Biotech AG   (Switzerland)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Measles virus; Recombinant vaccines; SARS; Viral vectors

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN; GLYCOPROTEIN S; LIVE VACCINE; MEASLES VACCINE; NEUTRALIZING ANTIBODY; NUCLEOCAPSID PROTEIN; RECOMBINANT VACCINE; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; ENZYME LINKED IMMUNOSPOT ASSAY; MEASLES; MEASLES VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TRANSGENIC MOUSE; VIROGENESIS; VIRUS RECOMBINANT; VIRUS TITRATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; GENETIC VECTORS; MEASLES VACCINE; MEASLES VIRUS; MEMBRANE GLYCOPROTEINS; MICE; NEUTRALIZATION TESTS; NUCLEOCAPSID PROTEINS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 41549161606     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.01.057     Document Type: Article

References (50)

1. Peiris J.S., Guan Y., and Yuen K.Y. Severe acute respiratory syndrome. Nat Med 10 (2004) S88-S97
2. Poon L.L., Guan Y., Nicholls J.M., Yuen K.Y., and Peiris J.S. The aetiology, origins, and diagnosis of severe acute respiratory syndrome. Lancet Infect Dis 4 (2004) 663-671
3. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300 (2003) 1394-1399
4. Xiao X., and Dimitrov D.S. The SARS-CoV S glycoprotein. Cell Mol Life Sci 61 (2004) 2428-2430
5. Takasuka N., Fujii H., Takahashi Y., Kasai M., Morikawa S., Itamura S., et al. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol 16 (2004) 1423-1430
6. Tang L., Zhu Q., Qin E., Yu M., Ding Z., Shi H., et al. Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol 23 (2004) 391-394
7. Zhou J., Wang W., Zhong Q., Hou W., Yang Z., Xiao S., et al. Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. Vaccine 23 (2005) 3202-3209
8. Zhou Z., Post P., Chubet R., Holtz K., McPherson C., Petric M., et al. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine 24 (2006) 3624-3631
9. Yang Z.Y., Kong W.P., Huang Y., Roberts A., Murphy B.R., Subbarao K., et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428 (2004) 561-564
10. Bisht H., Roberts A., Vogel L., Bukreyev A., Collins P.L., Murphy B.R., et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA 101 (2004) 6641-6646
11. Buchholz U.J., Bukreyev A., Yang L., Lamirande E.W., Murphy B.R., Subbarao K., et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA 101 (2004) 9804-9809
12. Bukreyev A., Lamirande E.W., Buchholz U.J., Vogel L.N., Elkins W.R., St Claire M., et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363 (2004) 2122-2127
13. Chen Z., Zhang L., Qin C., Ba L., Yi C.E., Zhang F., et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol 79 (2005) 2678-2688
14. Faber M., Lamirande E.W., Roberts A., Rice A.B., Koprowski H., Dietzschold B., et al. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J Gen Virol 86 (2005) 1435-1440
15. Radecke F., and Billeter M.A. Reverse genetics meets the nonsegmented negative-strand RNA viruses. Rev Med Virol 7 (1997) 49-63
16. Spielhofer P., Bachi T., Fehr T., Christiansen G., Cattaneo R., Kaelin K., et al. Chimeric measles viruses with a foreign envelope. J Virol 72 (1998) 2150-2159
17. Wang Z., Hangartner L., Cornu T.I., Zuniga A., Billeter M.A., and Naim H.Y. Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses. Vaccine 19 (2001) 2329-2336
18. Griffin D. Measles virus. 4th ed. (2001), Lippincott Williams & Wilkins, Philadelphia
19. Hilleman M.R. Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. Vaccine 20 (2002) 651-665
20. Ovsyannikova I.G., Dhiman N., Jacobson R.M., Vierkant R.A., and Poland G.A. Frequency of measles virus-specific CD4+ and CD8+T cells in subjects seronegative or highly seropositive for measles vaccine. Clin Diagn Lab Immunol 10 (2003) 411-416
21. Radecke F., Spielhofer P., Schneider H., Kaelin K., Huber M., Dotsch C., et al. Rescue of measles viruses from cloned DNA. EMBO J 14 (1995) 5773-5784
22. Singh M., Cattaneo R., and Billeter M.A. A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J Virol 73 (1999) 4823-4828
23. Neumeister C., Nanan R., Cornu T., Luder C., ter Meulen V., Naim H., et al. Measles virus and canine distemper virus target proteins into a TAP-independent MHC class I-restricted antigen-processing pathway. J Gen Virol 82 (2001) 441-447
24. Singh M., and Billeter M.A. A recombinant measles virus expressing biologically active human interleukin-12. J Gen Virol 80 (1999) 101-106
25. Despres P., Combredet C., Frenkiel M.P., Lorin C., Brahic M., and Tangy F. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis 191 (2005) 207-214
26. Zuniga A., Wang Z., Liniger M., Hangartner L., Caballero M., Pavlovic J., et al. Attenuated measles virus as a vaccine vector. Vaccine 25 (2007) 2974-2983
27. Lorin C., Mollet L., Delebecque F., Combredet C., Hurtrel B., Charneau P., et al. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J Virol 78 (2004) 146-157
28. Schneider-Schaulies S., and ter Meulen V. Measles and immunomodulations: molecular basis and perspectives. Expert Rev Mol Med 2002 (2002) 1-18
29. Schneider-Schaulies S., Klagge S.M., and ter Meulen V. Dendritic cells and measles virus infection. Curr Top Microbiol Immunol 276 (2003) 77-101
30. Calain P., and Roux L. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol 67 (1993) 4822-4830
31. Mrkic B., Pavlovic J., Rulicke T., Volpe P., Buchholz C.J., Hourcade D., et al. Measles virus spread and pathogenesis in genetically modified mice. J Virol 72 (1998) 420-7427
32. Albrecht P., Herrmann K., and Burns G.R. Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods 3 (1981) 251-260
33. Gao W., Tamin A., Soloff A., D'Aiuto L., Nwanegbo E., Robbins P.D., et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 362 (2003) 1895-1896
34. Sui J., Li W., Murakami A., Tamin A., Matthews L.J., Wong S.K., et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci USA 101 (2004) 2536-2541
35. Dilraj A., Cutts F.T., de Castro J.F., Wheeler J.G., Brown D., Roth C., et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. Lancet 355 (2000) 798-803
36. Gans H., Yasukawa L., Rinki M., DeHovitz R., Forghani B., Beeler J., et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis 184 (2001) 817-826
37. Gans H., DeHovitz R., Forghani B., Beeler J., Maldonado Y., and Arvin A.M. Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine 21 (2003) 3398-3405
38. Sepulveda-Amor J., Valdespino-Gomez J.L., Garcia-Garcia M.L., Bennett J., Islas-Romero R., Echaniz-Aviles G., et al. A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children. Vaccine 20 (2002) 2790-2795
39. See R.H., Roper R.L., Brunham R.C., and Finlay B.B. Rapid response research_SARS coronavirus vaccines and application of processes to other emerging infectious diseases. Curr Immunol Rev 1 (2005) 185-200
40. Marshall E., and Enserink M. Caution urged on SARS vaccines. Science 303 (2004) 944-946
41. Olsen C.W. A review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects, and vaccination. Vet Microbiol 36 (1993) 1-37
42. Pedersen N.C., and Black J.W. Attempted immunization of cats against feline infectious peritonitis, using avirulent live virus or sublethal amounts of virulent virus. Am J Vet Res 44 (1983) 229-234
43. Vennema H., de Groot R.J., Harbour D.A., Dalderup M., Gruffydd-Jones T., Horzinek M.C., et al. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Virol 64 (1990) 1407-1409
44. Weingartl H., Czub M., Czub S., Neufeld J., Marszal P., Gren J., et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol 78 (2004) 12672-12676
45. Liu S.J., Leng C.H., Lien S.P., Chi H.Y., Huang C.Y., Lin C.L., et al. Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates. Vaccine 24 (2006) 3100-3108
46. Holmes K.V. SARS coronavirus: a new challenge for prevention and therapy. J Clin Invest 111 (2003) 1605-1609
47. Sestak K., Meister R.K., Hayes J.R., Kim L., Lewis P.A., Myers G., et al. Active immunity and T-cell populations in pigs intraperitoneally inoculated with baculovirus-expressed transmissible gastroenteritis virus structural proteins. Vet Immunol Immunopathol 70 (1999) 203-221
48. Kim T.W., Lee J.H., Hung C.F., Peng S., Roden R., Wang M.C., et al. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol 78 (2004) 4638-4645
49. Bennett J.V., Fernandez D.C., Valdespino-Gomez J.L., Garcia-Garcia M.L., Islas-Romero R., Echaniz-Aviles G., et al. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren. Bull World Health Organ 80 (2002) 806-812
50. Tangy F., and Naim H.Y. Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector. Viral Immunol 18 (2005) 317-326